Gyre Therapeutics Presents Strong Preclinical Data for Cancer Degrader CG923308, Targets Q1 2027 IND
GYRE is trading near its 52-week low of $6.57 (6.5% above the low) on elevated volume (2.2× avg).
Summary
Gyre Therapeutics presented strong preclinical data for its cancer drug candidate, CG923308, at a scientific conference, demonstrating its potential in solid tumors and resistant breast cancer, with an IND submission targeted for Q1 2027.
Key Events · Product Development and Regulatory · GYRE
-
Scientific Presentation Furnished
Gyre Therapeutics will present detailed preclinical data for its drug candidate CG923308 at a scientific conference in Shanghai, China on May 15, 2026.
-
Strong Preclinical Data for CG923308
The presentation highlights CG923308, a CDK2-Cyclin E Degrader, showing potent and selective degradation in multiple cancer types and superior anti-cancer efficacy over Phase 2/3 CDK2 inhibitors in preclinical models.
-
Targeting Solid Cancers and Resistant Breast Cancer
CG923308 is being developed for solid tumors with CCNE1 amplification and HR+/HER2- breast cancer resistant to CDK4/6 inhibitors, addressing significant unmet clinical needs.
-
IND Submission Anticipated Q1 2027
Cullgen, a subsidiary of Gyre Therapeutics, anticipates submitting an Investigational New Drug (IND) application for CG923308 in the first quarter of 2027.
Analysis · GYRE · Life Sciences
This 8-K furnishes a scientific presentation detailing robust preclinical data for CG923308, a lead asset acquired through the recent Cullgen Inc. acquisition. The data suggests CG923308, a CDK2-Cyclin E Degrader, shows superiority over existing Phase 2/3 CDK2 inhibitors in treating solid cancers and breast cancer resistant to CDK4/6 inhibitors. The announcement of an anticipated Investigational New Drug (IND) application submission in Q1 2027 provides a clear development timeline for this potentially significant therapeutic, validating the strategic value of the Cullgen acquisition.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GYRE was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $679M. The 52-week trading range was $6.57 to $11.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.